losartan has been researched along with Psoriasis in 8 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topical Losartan1% significantly alleviates psoriasis by reducing AT1R and IL-17a expression." | 8.02 | Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation. ( Abdollahifar, MA; Dehpour, AR; Haddadi, NS; Hedayatyanfard, K; Kazemi, K; Shayan, M; Shokrian Zeini, M; Solaimanian, S, 2021) |
| "Psoriasis has a similar prevalence in hypertensive patients as in the general population." | 6.79 | Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. ( Bang, CN; Devereux, RB; Gottlieb, AB; Køber, L; Okin, PM; Wachtell, K, 2014) |
| "Psoriasis is a papulosquamous disease of multifactorial etiology." | 6.47 | Psoriasis induced by losartan therapy: a case report and review of the literature. ( Charrow, EJ; Forman, L; Lal, S; Lamba, G; Palaniswamy, C; Shah, D; Singh, T; Vinnakota, R, 2011) |
| "Topical Losartan1% significantly alleviates psoriasis by reducing AT1R and IL-17a expression." | 4.02 | Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation. ( Abdollahifar, MA; Dehpour, AR; Haddadi, NS; Hedayatyanfard, K; Kazemi, K; Shayan, M; Shokrian Zeini, M; Solaimanian, S, 2021) |
| "Psoriasis has a similar prevalence in hypertensive patients as in the general population." | 2.79 | Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. ( Bang, CN; Devereux, RB; Gottlieb, AB; Køber, L; Okin, PM; Wachtell, K, 2014) |
| "Psoriasis is a papulosquamous disease of multifactorial etiology." | 2.47 | Psoriasis induced by losartan therapy: a case report and review of the literature. ( Charrow, EJ; Forman, L; Lal, S; Lamba, G; Palaniswamy, C; Shah, D; Singh, T; Vinnakota, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Shokrian Zeini, M | 2 |
| Haddadi, NS | 1 |
| Shayan, M | 1 |
| Kazemi, K | 1 |
| Solaimanian, S | 1 |
| Abdollahifar, MA | 1 |
| Hedayatyanfard, K | 1 |
| Dehpour, AR | 1 |
| Bang, CN | 1 |
| Okin, PM | 1 |
| Køber, L | 1 |
| Wachtell, K | 1 |
| Gottlieb, AB | 1 |
| Devereux, RB | 1 |
| Angeli, F | 1 |
| Reboldi, G | 1 |
| Verdecchia, P | 1 |
| Lüscher, TF | 1 |
| Matsushima, T | 1 |
| Nakajima, H | 1 |
| Ohko, K | 1 |
| Nakajima, K | 1 |
| Sano, S | 1 |
| Lamba, G | 1 |
| Palaniswamy, C | 1 |
| Singh, T | 1 |
| Shah, D | 1 |
| Lal, S | 1 |
| Vinnakota, R | 1 |
| Charrow, EJ | 1 |
| Forman, L | 1 |
| Marquart-Elbaz, C | 1 |
| Grosshans, E | 1 |
| Lipsker, D | 2 |
| Saraceno, R | 1 |
| Citarella, L | 1 |
| Spallone, G | 1 |
| Chimenti, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Psoriasis
| Article | Year |
|---|---|
Psoriasis induced by losartan therapy: a case report and review of the literature.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non- | 2011 |
1 trial available for losartan and Psoriasis
| Article | Year |
|---|---|
Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Double- | 2014 |
6 other studies available for losartan and Psoriasis
| Article | Year |
|---|---|
Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation.
Topics: Administration, Cutaneous; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agent | 2021 |
Hypertension, inflammation and atrial fibrillation.
Topics: Antihypertensive Agents; Atrial Fibrillation; Female; Humans; Hypertension; Hypertrophy, Left Ventri | 2014 |
Atherosclerosis, neoatherosclerosis, and vascular disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Aortic Valve Stenosis; Cardiovascular Dise | 2015 |
Chlorothiazide-induced photoaggravation of psoriatic lesion during narrowband ultraviolet B treatment in a case of psoriasis vulgaris.
Topics: Aged; Disease Progression; Drug Combinations; Female; Ficusin; Humans; Hydrochlorothiazide; Hyperten | 2017 |
Sartans, angiotensin II receptor antagonists, can induce psoriasis.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Drug Eruptions; Female; Humans; Los | 2002 |
A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Deri | 2008 |